Сравнение

Octreotide vs. Pasireotid

Два пептида рядом — идентичность, доказательная база, правовой статус и известные нежелательные явления.

Идентичность

Категория

Исследования (прочее)

Номер CAS

83150-76-9

396091-73-9

Молекулярная масса

1019.24 g/mol

1047.21 g/mol

Период полувыведения

1.7 h

нет данных

Последовательность

D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Thr(ol)

нет данных

Механизм действия

Octreotide

Octreotide is a cyclic octapeptide that selectively binds somatostatin-receptor subtypes SSTR2 and SSTR5. Via G-protein-coupled signalling, adenylyl cyclase is inhibited, reducing the secretion of multiple hormones (growth hormone, IGF-1, glucagon, insulin, VIP, serotonin). Structural stabilisation via a disulfide bridge and D-amino acids extends the half-life relative to natural somatostatin (minutes to several hours).

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Доказательная база

Наивысшая доказательность

РКИ на людях

Исследования

из них на людях

Зафиксированные эффекты

Открытые противоречия

Задокументированные нежелательные явления

Правовой статус

Country	Octreotide	Pasireotid
Германия	Рецептурный	Рецептурный
США	Рецептурный	Рецептурный

Полные записи

Frequently asked questions

What is the difference between Octreotide and Pasireotid?: Octreotide is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Octreotide or Pasireotid?: The highest available evidence level is "РКИ на людях" for Octreotide and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Octreotide and Pasireotid in Germany and the United States?: Германия: Octreotide — Рецептурный, Pasireotid — Рецептурный. США: Octreotide — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.

Country

Octreotide

Pasireotid

Германия

Рецептурный

США

Рецептурный

Frequently asked questions

What is the difference between Octreotide and Pasireotid?

Octreotide is classified as "Исследования (прочее)", while Pasireotid is classified as "Исследования (прочее)". Octreotide: Synthetic octapeptide somatostatin analog with a longer half-life than endogenous somatostatin. FDA- and EMA-approved since the 1980s for acromegaly and neuroendocrine tumours. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Octreotide or Pasireotid?

The highest available evidence level is "РКИ на людях" for Octreotide and "РКИ на людях" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Octreotide and Pasireotid in Germany and the United States?

Германия: Octreotide — Рецептурный, Pasireotid — Рецептурный. США: Octreotide — Рецептурный, Pasireotid — Рецептурный. These are factual summaries with source and review date on the individual pages.